View the PROSPECT II and PROSPECT ABSORB study results as presented at TCT Connect.LEARN MORE LEARN MORE

Our Culture

Charting the uncharted territories of vascular disease doesn’t happen overnight. It takes passion, grit, and heart to never stop seeking solutions. The kind of determination that has fueled Infraredx for nearly 30 years.


Our Leadership

Nozomu “Fuji” Fujita

President and CEO, Infraredx, a Nipro Company General Manager, Nipro Vascular Business Division

Having been employed at Nipro for nearly 25 years, Nozomu Fujita takes the Nipro creed of “Willingness” to heart. He joined the company immediately after earning his master’s degree in engineering from the Department of Applied Chemistry at the esteemed Osaka Institute of Technology, and his career grew as Nipro continued to expand.

Steve Sum, PhD

Sr. Vice President of Technology Innovation and Regulatory

Steve Sum is an academic at heart. After earning a BSc in Chemistry & Mathematics at the University of Waterloo in Ontario, Canada, he went straight on to earn a MSc in Information & Systems Science from Carleton University, and then a PhD in Chemometrics and Analytical Chemistry from the University of Delaware.

David Barone

Vice President of Product Development

If not for his love of music, David Barone might never have joined Infraredx. When then-Director of Catheter R&D, Jerry Brightbill, asked him to play drums with his band for the Infraredx holiday party in 2005, David found himself at founder Jim Muller’s home, surrounded by the entire company. Brightbill, who plays guitar had joined Infraredx a few years earlier and, during jam sessions, would often ask David to check them out.


Don’t Guess. See.

Gain twice the insights into Coronary Artery Disease with IVUS+NIRS. See how combination IVUS+NIRS imaging offers cardiologists unparalleled insights into the role LCP plays in heart disease.

Amid COVID-19 concerns, we are unable to exhibit in person and will be participating in virtual conferences. Please check back periodically for event updates or for more information send us an email

March 5, 2021
New Avenues for the Detection and Treatment of Vulnerable Plaque Virtual Webinar
Virtual CME-accredited program
Presented via Zoom at 8:00am ET
March 27, 2021
CRT 2021: Live Case Session
Broadcasting live from MedStar Washington Hospital Center
Presented virtually at 8:00am ET
March 27, 2021
CRT 2021
Focused Session: Detection of Vulnerable Plaque
Presented virtually at 9:00am ET


Results of the PROSPECT II Natural History Study Demonstrate High-Risk Plaques Identified by NIRS+IVUS Imaging are Linked to Future Coronary Events

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The PROSPECT II study demonstrated the ability of near-infrared spectroscopy (NIRS) imaging plus intravascular ultrasound (IVUS) to identify coronary plaques responsible for future coronary events. The randomized substudy PROSPECT ABSORB, which was simultaneously published in the Journal of the American College of Cardiology (JACC), showed treatment of high-risk vulnerable plaques with a bioresorbable vascular scaffold (BVS) was safe and substantially associated with favorable long-term clinical outcomes compared to guideline-directed medical therapy (GDMT) alone.

Read More
Dr. Giulio Guagliumi discusses the “use of IVUS+NIRS imaging for decision making in acute coronary syndrome.” 

Dr. Giulio Guagliumi from ASST Papa Giovanni XXIII in Bergamo, Italy discusses the “use of IVUS+NIRS imaging for decision making in acute coronary syndrome,” during the 2020 EuroPCR e-course. The course discusses:

  • The frequency of culprit lesion ambiguity in ACS
  • The value of IVUS+NIRS imaging in challenging scenarios
  • Integrating the information provided by IVUS+NIRS imaging in the clinical decision-making process.
Read More
COVID-19 Pandemic – Message from our President & CEO

The safety and well-being of our employees and partners is always our number one priority, as is continuing to deliver quality care to your patients. Our goal is to ensure that we maintain the highest level of support for you during this unprecedented time.

Read More
Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE

Study in The Lancet successfully demonstrated endpoints of identifying both vulnerable patients and vulnerable plaques that are at significantly higher risk for subsequent major adverse cardiovascular events.

Read More


Thank you for your interest in employment opportunities at Infraredx, a Nipro Company.

We are happy to receive your application. If you are interested in future opportunities, please send your CV to

© 2020 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative